Pediatric Neurology
Volume 42, Issue 3 , Pages 187-195 , March 2010

Cognitive Effects of Topiramate in Migraine Patients Aged 12 Through 17 Years

  • Gahan J. Pandina, PhD

      Affiliations

    • Johnson & Johnson Pharmaceutical Research & Development L.L.C, Titusville, New Jersey
    • Corresponding Author InformationCommunications should be addressed to: Dr. Pandina; Clinical Leader, Psychiatry; Johnson & Johnson Pharmaceutical Research & Development; 1125 Trenton-Harbourton Road; Titusville, NJ 08560.
    • ,
  • Seth Ness, MD, PhD

      Affiliations

    • Johnson & Johnson Pharmaceutical Research & Development L.L.C, Titusville, New Jersey
    • ,
  • Elena Polverejan, PhD

      Affiliations

    • Johnson & Johnson Pharmaceutical Research & Development L.L.C, Titusville, New Jersey
    • ,
  • Eric Yuen, MD

      Affiliations

    • Johnson & Johnson Pharmaceutical Research & Development L.L.C, Titusville, New Jersey
    • ,
  • Marielle Eerdekens, MD

      Affiliations

    • Johnson & Johnson Pharmaceutical Research & Development L.L.C, Beerse, Antwerp, Belgium
    • ,
  • Robert M. Bilder, PhD

      Affiliations

    • Geffen School of Medicine at University of California-Los Angeles, Los Angeles, California
    • ,
  • Lisa Ford, MD

      Affiliations

    • Johnson & Johnson Pharmaceutical Research & Development L.L.C, Titusville, New Jersey

Received 9 June 2009 ,Accepted 12 October 2009.

References 

  1. Lewis D, Winner Paul, Saper J, et al. Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of topiramate for migraine prevention in pediatric subjects 12 to 17 years of age. Pediatrics. 2009;123:924–934
  2. Apostol G, Cady R, Laforet G, et al. Divalproex extended-release in adolescent migraine prophylaxis: results of a randomized, double-blind, placebo-controlled study. Headache. 2008;48:1012–1025
  3. Golden AS, Haut SR, Moshé SL. Nonepileptic uses of antiepileptic drugs in children and adolescents. Pediatr Neurol. 2006;34:421–432
  4. Ortho-McNeil . Topamax. [package insert] Titusville, NJ: Ortho-McNeil Neurologics; 2005;
  5. Silberstein SD, Neto W, Schmitt J, Jacobs D. MIGR-001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol. 2004;61:490–495
  6. Brandes JL, Saper JR, Diamond M, et al. MIGR-002 Study Group. Topiramate for migraine prevention: a randomized controlled trial. JAMA. 2004;291:965–973
  7. Diener HC, Tfelt-Hansen P, Dahlof C, et al. MIGR-003 Study Group. Topiramate in migraine prophylaxis: results from a placebo-controlled trial with propranolol as an active control. J Neurol. 2004;251:943–950
  8. Silberstein SD, Lipton RB, Dodick DW, et al. Topiramate Chronic Migraine Study Group. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache. 2007;47:170–180
  9. Diener HC, Bussone G, Van Oene J, Lahaye M, Schwalen S, Goadsby P. TOPMAT-MIG-201 (TOP-CHROME) Study Group. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. [Erratum in: Cephalalgia 2007;27:962] Cephalalgia. 2007;27:814–823
  10. Thompson PJ, Baxendale SA, Duncan JS, Sander JW. Effects of topiramate on cognitive function. J Neurol Neurosurg Psychiatry. 2000;69:636–641
  11. Meador KJ, Loring DW, Hulihan JF, Kamin M, Karim R. CAPSS-027 Study Group. Differential cognitive and behavioral effects of topiramate and valproate. Neurology. 2003;60:1483–1488
  12. Lee HW, Jung DK, Suh CK, Kwon SH, Park SP. Cognitive effects of low-dose topiramate monotherapy in epilepsy patients: a 1-year follow-up. Epilepsy Behav. 2006;8:736–741
  13. Martin R, Kuzniecky R, Ho S, et al. Cognitive effects of topiramate, gabapentin and lamotrigine in healthy young adults. Neurology. 1999;52:321–327
  14. Blum D, Meador K, Biton V, et al. Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy. Neurology. 2006;67:400–406
  15. Gomer B, Wagner K, Frings L, et al. The influence of antiepileptic drugs on cognition: a comparison of levetiracetam with topiramate. Epilepsy Behav. 2007;10:486–494
  16. Bourgeois BF. Determining the effects of antiepileptic drugs on cognitive function in pediatric patients with epilepsy. J Child Neurol. 2004;19(Suppl. 1):S15–S24
  17. Aarsen FK, van den Akker EL, Drop SL, Catsman-Berrevoets CE. Effect of topiramate on cognition in obese children. Neurology. 2006;67:1307–1308
  18. de Araujo Filho GM, Pascalicchio TF, Lin K, Sousa PS, Yacubian EM. Neuropsychiatric profiles of patients with juvenile myoclonic epilepsy treated with valproate or topiramate. Epilepsy Behav. 2006;8:606–609
  19. Sirén A, Kylliäinen A, Tenhunen M, Hirvonen K, Riita T, Koivikko M. Beneficial effects of antiepileptic medication on absence seizures and cognitive functioning in children. Epilepsy Behav. 2007;11:85–91
  20. Shorvon SD. Safety of topiramate: adverse events and relationships to dosing. Epilepsia. 1996;37(Suppl. 2):S18–S22
  21. Edwards KR, Kamin M. Topiramate TPS-TR Study Group. The beneficial effect of slowing the initial titration rate of topiramate. [Abstract] Neurology. 1997;48(Suppl. 2):A39
  22. Silberstein SD. Topiramate in migraine prevention. Headache. 2005;45(Suppl. 1):S57–S65
  23. De Luca CR, Wood SJ, Anderson V, et al. Normative data from the CANTAB. I: development of executive function over the lifespan. J Clin Exp Neuropsychol. 2003;25:242–254
  24. Luciana M, Nelson CA. The functional emergence of prefrontally-guided working memory systems in four-to- eight year-old children. Neuropsychologia. 1998;36:273–293
  25. Luciana M, Nelson CA. Neurodevelopmental assessment of cognitive function using CANTAB: validation and future goals. In:  Ernst M,  Rumsey J editor. Coyle J, forward. Functional neuroimaging in child psychiatry. New York: Cambridge University Press; 2000;p. 380–392
  26. Luciana M, Nelson CA. Assessment of neuropsychological function through use of the Cambridge Neuropsychological Testing Automated Battery: performance in 4- to 12-year-old children. Dev Neuropsychol. 2002;22:595–624
  27. Haverkamp F, Hönscheid A, Müller-Sinik K. Cognitive development in children with migraine and their healthy unaffected siblings. Headache. 2002;42:776–779
  28. Riva D, Aggio F, Vago C, et al. Cognitive and behavioural effects of migraine in childhood and adolescence. Cephalalgia. 2006;26:596–603
  29. Zgorzalewicz M, Mojs E. Assessment of chosen cognitive functions in children and adolescents with primary headaches. [in Polish] Przegl Lek. 2006;63(Suppl. 1):24–28
  30. Abu-Arefeh I, Russell G. Prevalence of headache and migraine in schoolchildren. BMJ. 1994;309:765–769
  31. Salthouse TA. Implications of within-person variability in cognitive and neuropsychological functioning for the interpretation of change. Neuropsychology. 2007;21:401–411
  32. Tfelt-Hansen P, Block G, Dahlöf C, et al. International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia. 2000;20:765–786
  33. Headache Classification Subcommittee; International Headache Society. The International Classification of Headache Disorders, 2nd edition. Cephalalgia. 2004;24(Suppl. 1):9–160
  34. Wasiewski WW, Rothner AD. Pediatric migraine headache diagnosis, evaluation, and management. Neurologist. 1999;5:122–134
  35. Dickstein DP, Treland JE, Snow J, et al. Neuropsychological performance in pediatric bipolar disorder. Biol Psychiatry. 2004;55:32–39
  36. Ritchie K, Allard M, Huppert FA, Nargeot C, Pinek B, Ledésert B. Computerized cognitive examination of the elderly (ECO): The development of a neuropsychological examination for clinic and population use. Int J Geriatric Psychiatry. 1993;8:899–914
  37. Curran SL, Andrykowski MA, Studts JL. Short form of the Profile of Mood States (POMS-SF): Psychometric information. Psychol Assess. 1995;7:80–83
  38. Winner P, Rothner AD, Putnam DG, Asgharnejad M. Demographic and migraine characteristics of adolescents with migraine: Glaxo Wellcome clinical trials' database. Headache. 2003;43:451–457
  39. Powers SW, Patton SR, Hommel KA, Hershey AD. Quality of life in childhood migraines: clinical impact and comparison to other chronic illnesses. Pediatrics. 2003;112:e1–e5
  40. Powers SW, Patton SR, Hommel KA, Hershey AD. Quality of life in paediatric migraine: characterization of age-related effects using PedsQL 4.0. Cephalalgia. 2004;24:120–127
  41. Lindman JP, Lewis LS, Accortt N, Wiatrak BJ. Use of the Pediatric Quality of Life Inventory to assess the health-related quality of life in children with recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol. 2005;114:499–503
  42. MacDonald RL, McLean MJ. Anticonvulsant drugs: mechanisms of action. Adv Neurol. 1986;44:713–736
  43. Rogawski MA, Porter RJ. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising development stage compounds. Pharmacol Rev. 1990;42:223–286
  44. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH. Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia. 2000;41(Suppl. 1):S17–S20
  45. Lowe C, Rabbitt P. Test/re-test reliability of the CANTAB and ISPOCD neuropsychological batteries: theoretical and practical issues. Cambridge Neuropsychological Test Automated Battery. International Study of Post-Operative Cognitive Dysfunction. Neuropsychologia. 1998;36:915–923
  46. Louis WJ, Mander AG, Dawson M, O'Callaghan C, Conway EL. Use of computerized neuropsychological tests (CANTAB) to assess cognitive effects of antihypertensive drugs in the elderly. Cambridge Neuropsychological Test Automated Battery. J Hypertens. 1999;17:1813–1819
  47. Bird CM, Papadopoulou K, Ricciardelli P, Rossor MN, Cipolotti L. Monitoring cognitive changes: psychometric properties of six cognitive tests. Br J Clin Psychol. 2004;43:197–210
  48. Collie A, Maruff P, Darby DG, McStephen M. The effects of practice on the cognitive test performance of neurologically normal individuals assessed at brief test-retest intervals. J Int Neuropsychol Soc. 2003;9:419–428
  49. Luciana M. Practitioner review: computerized assessment of neuropsychological function in children: clinical and research applications of the Cambridge Neuropsychological Testing Automated Battery (CANTAB). J Child Psychol Psychiatry. 2003;44:649–663

PII: S0887-8994(09)00481-0

doi: 10.1016/j.pediatrneurol.2009.10.001

Pediatric Neurology
Volume 42, Issue 3 , Pages 187-195 , March 2010

Article Tools

* Image Usage & Resolution